Essentials
• Antiangiogenic drugs are indicated as therapies for hereditary hemorrhagic telangiectasia.
• We interrogated the response to four antiangiogenic drugs for anemia and intestinal bleeding.
• Sorafenib and a pazopanib analog significantly improved while erlotinib worsened anemia.
• Some oral antiangiogenic drugs were effective in reducing intestinal bleeding.
Summary. Background: Epistaxis and gastrointestinal (GI) tract hemorrhages are common symptoms of aged hereditary hemorrhagic telangiectasia (HHT) patients that result in anemia. Clinical as well as animal studies have suggested that vascular endothelial growth factor (VEGF) neutralizing antibodies lessen hemorrhage associated with adult-onset arteriovenous malformations (AVMs). Objectives: The goal of this study is to evaluate potential therapeutic effects of oral delivery of four antiangiogenic tyrosine-kinase inhibitors (TKIs) in the development of adult-onset AVMs in a murine model of HHT. Methods: An adult activin receptor-like kinase 1 (Alk1)-inducible knockout (iKO) model was utilized to evaluate the effect of oral administration of sorafenib, sunitinib, erlotinib and a pazopanib analog (GW771806) on hemoglobin level, GI hemorrhages and formation of wound-induced skin AVMs. Results and Conclusions: Sorafenib and GW771806 significantly improved, yet erlotinib worsened, anemia and GI-bleeding in the Alk1-iKO model. However, none of these TKIs appeared to be effective for inhibiting the development of wound-induced skin AVMs. Taken together, these results suggest that oral delivery of antiangiogenic TKIs is selectively more effective for GI bleeding than mucocutaneous AVMs, and it may provide an experimental basis for selective therapeutic options depending on the symptoms of HHT.
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Introduction
Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Rendu-Weber syndrome, is an autosomal dominant vascular disorder with mutations in endoglin (ENG), activin receptor-like kinase 1 (ACVRL1; ALK1) or SMAD4 [1] [2] [3] . It affects about 1 in 5000-8000 individuals worldwide. Arteriovenous malformation (AVM), an abnormal connection between arteries and veins, produces vulnerable lesions that may rupture and/ or alter blood flow, resulting in the dramatic clinical symptoms of cerebral hemorrhage, pulmonary shunts, or heart failure. The clinical symptoms of HHT include epistaxis, mucocutaneous telangiectases and hemorrhages of internal organs such as the gastrointestinal (GI) tract. The incidence and severity of epistaxis and mucocutaneous telangiectasia get higher with age as more than 90% of HHT patients over the age of 60 experience epistaxis [4] . Epistaxis and GI bleeding often result in anemia, iron deficiency and the need for blood transfusions, leading to a substantial compromise in the quality of life. New treatment modalities are essential, as the current therapeutic options for treating these HHT symptoms are limited.
Tamoxifen-inducible global (R26 CreER ;Alk1 2f/2f ) or endothelial cell-specific (Scl-CreER;Alk1 2f/2f ) Alk1-deletion recapitulated HHT phenotypes, including GI and lung hemorrhages with associated anemia [5, 6] . However, the vascular anomalies in Alk1 or Eng-deficient adult skin and brains formed only in the presence of additional insults such as excisional wounds or proangiogenic stimulation by vascular endothelial growth factor (VEGF) [5, 7, 8] . Conversely, VEGF blockades could alleviate wound-induced AVMs and GI bleeding in the Alk1-inducible knockout (iKO) model [7] .
Increased levels of VEGF have been detected in the plasma [9] and serum [10] of HHT patients. It was found that there was a correlation of these levels with the intensity of VEGF staining and microvessel density in their respective nasal mucosae [9] . Intravenous, submucosal and topical bevacizumab (a monoclonal antibody against VEGF-A) treatments have been shown to be effective in reducing nasal bleeds, quantified by the improvement in an epistaxis severity index [11] [12] [13] [14] . However, recent randomized clinical trials of short-term use of bevacizumab nasal spray revealed no significant benefit for epistaxis [15, 16] . Tyrosine-kinase inhibitors (TKIs) target receptor tyrosine kinases such as VEGF receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs) and epidermal growth factor receptor (EGFR). These drugs have been used as antiangiogenic and anti-cancer drugs for renal cell carcinoma (sunitinib, sorafenib and pazopanib), gastrointestinal stromal tumor (sunitinib), unresectable hepatocellular carcinoma (sorafenib), soft tissue sarcoma (pazopanib) and metastatic non-small-cell lung cancer and pancreatic cancer (erlotinib) [17] [18] [19] [20] [21] [22] . Essentially, blockade of angiogenesis in the setting of a solid tissue tumor can limit the growth of the tumor itself.
We assessed the therapeutic potential of antiangiogenic pharmaceutical drugs, including antiangiogenic small molecules (erlotinib, sorafenib, sunitinib and a pazopanib analog) for GI bleeding and mucocutaneous AVMs using an HHT mouse model. The results from this preclinical animal model may provide insights into clinical symptomdependent drug selection for treating HHT.
Materials

Animals
All in vivo procedures were conducted in accordance with animal use guidelines established by the University of Florida Institutional Animal Care and Use Committee. Establishment of the Alk1 2f allele in laboratory mice was described previously [23] . R26
CreER mice were purchased from the Jackson Laboratory. R26
CreER/+ , Alk1 2f/2f mice used in this study were on a mixed (129SvJ/C57BL6) background.
Skin wound generation and drug treatment
Full-thickness skin wounds were created in the mid-dorsum of mice with a sterile disposable biopsy punch (3 mm diameter). Tamoxifen was injected intraperitoneally at 100 mg kg À1 of body weight (b.w.) on the day of wounding (Day 0 
Latex dye injection and image processing
The procedure for latex dye perfusion and image processing is the same as previously described [5, 7] .
Hemoglobin concentration and GI hemorrhage index
Hemoglobin (Hb) concentrations in the blood collected from mouse tails were measured by a hemoglobin photometer (Hemopoint H2, STANBIO Laboratory, Boerne, TX, USA).
Hyperspectral image acquisition and processing
The surgical procedure for the window chamber installation, image acquisition and processing has been described previously [6, 7] .
Statistics
Data were represented as mean AE standard deviation (SD). One-way ANOVA with post-Tukey multiple comparison tests (GraphPad Prism 4.03, GraphPad Software, San Diego, CA, USA) was used to analyze Hb and GI bleeding results. Student's t-test was also used to determine a statistical significance between two groups with at least three pairs. A value of P < 0.05 was considered statistically significant (*P < 0.05, **P < 0.01 and ***P < 0.001).
Results and discussion
Oral administration of sorafenib or GW771806 improves low hemoglobin caused by Alk1-depletion
We evaluated the efficacy of oral treatment with FDAregistered antiangiogenic TKIs (erlotinib, sunitinib and sorafenib), as well as a pazopanib-like agent (GW771806), on HHT symptoms using the Alk1-iKO mouse model (R26
). In this model, tamoxifen administration produces an ALK1 deficiency, which results in GI bleeding, anemia and wound-induced skin AVMs in 6-8 days. Because one of the most common and severe systemic HHT symptoms is anemia, we examined hemoglobin (Hb) levels. Hb levels before tamoxifen treatment (day 0) of control groups varied in the range of 11 to 17 g dL
À1
( Fig. 1A and B) . The means of the DMSO and vehicle control groups were 12.94 g dL À1 (n = 13) and 14.17 g dL
(n = 10), respectively. These mean values dropped to 4.48 g dL À1 and 5.37 g dL
, respectively, 8 days after tamoxifen treatment. The TKI-treated groups also had the similar trend of reduced Hb levels after Alk1 deletion, but the magnitude of reduction was different among groups. Percentage reduction of Hb levels during 8 days in the sorafenib-treated (n = 12; 40.38%; Fig. 1C ) and the GW771806-treated (n = 12; 41.65%; Fig. 1D ) groups was significantly less than that observed in the control groups (DMSO 65.04% [Fig. 1C] ; vehicle 59.59% [Fig. 1D]) . The sunitinibtreated group (n = 12; 58.01%) also exhibited a similar trend toward improvement of Hb levels compared with the controls (Fig. 1C) but did not reach significance. On the other hand, the erlotinib group (n = 8) revealed lower Hb levels than the DMSO-treated group (Fig. 1C) . Erlotinib targets epidermal growth factor receptor. Recent studies demonstrated that erlotinib induces barrier dysfunction of small intestine epithelial cells and enhances ER-stress-mediated intestinal epithelial injury [24] . We speculate that the adverse effect of erlotinib could be a result of combined effects of erlotinb on both intestinal epithelial cells and angiogenesis. To test the potency of the drug in producing the effect, we examined one TKI, GW771806, at progressively lower dosing levels in addition to the previous 40-mg dose. Although only the highest dose (40 mg kg À1 bw) demonstrated significance, all treated groups showed a similar trend of improving hemoglobin levels compared with the vehicle-treated group, perhaps suggesting a Type II error or lack of significance because of small numbers.
Oral administration of sunitinib, sorafenib or GW771806 ameliorates GI bleeding caused by Alk1-depletion GI bleeding seems to be a key contributor to the anemia symptoms seen in Alk1-iKO mice [5] . To examine the severity of GI bleeding, the entire GI tract from the stomach to colon was examined, and categorized into three groups according to severity determined by darkness of brown color in the colon and cecum area: none (score = 0), weak-moderate (score = 1) and moderatestrong (score = 2) ( Fig. 2A ; Figure S1 ). As shown in Fig. 2B , the GI bleeding index results are well correlated with hemoglobin levels in TKI-treated mice. All mice in the erlotinib-treated group displayed more severe GI bleeding (average, 2; P < 0.001; n = 12) than the DMSOtreated mice (Fig. 1A and 2B ). In contrast, sorafenib (average, 0; P < 0.001; n = 12) and GW771806 (average, 0; P < 0.01; n = 12) reduced GI bleeding compared with DMSO (average, 1.15; n = 13) and vehicle (average, 0.9; n = 10), respectively ( Fig. 2B and C) . The sunitinib-treated group also showed significantly less GI bleeding (average, 0.5; P < 0.05; n = 12; Fig. 2B ).
Oral administration of antiangiogenic TKIs was unable to suppress the formation of wound-induced skin AVMs
Unlike the GI tract, AVMs in the subdermal vasculature develop in the setting of a secondary insult such as wounding in the Alk1-iKO model [5] . We have previously shown that VEGF could mimic the wound effect and VEGF neutralizing antibodies could inhibit woundinduced skin AVMs in the Alk1-iKO model [7] . Because sorafenib, pazopanib and sunitinib are known as strong inhibitors of VEGF receptors, we examined whether the oral administration of TKIs would have a similar effect with VEGF antibodies in inhibiting the development of wound-induced AVMs. Unexpectedly, treatment with the four TKIs did not inhibit wound-induced skin AVMs (Fig. 3) . It appeared that sorafenib treatment slightly increased the vascular density (Fig. 3C ). This result might be related to the report showing that sorafenib treatment (30 mg kg À1 daily) led to intratumoral recruitment of F4/ 80-and CD11b-positive macrophages, which secrete cytokines for promoting a proangiogenic microenvironment [25] . Clinical as well as animal studies have suggested that angiogenic stimulation is a critical environmental factor for the development of AVMs in HHT [5, 7] , and that antiangiogenic blockades are effective therapies for prevalent HHT symptoms, such as epistaxis, GI bleeding and liver AVMs [7, 11, 13, 14, 26] . In this study, we evaluated the efficacy of the potent antiangiogenic TKIs using the Alk1-iKO mice to diversify therapeutic options for HHT. Sorafenib and GW771806 administration significantly improved Hb and GI bleeding, whereas they were not effective in preventing wound-induced skin AVMs. Although sunitinib treatment did not reach a statistically significant level, it also showed a tendency to improve the Hb level and ameliorated GI bleeding. In contrast, oral administration of erlotinib, an EGFR inhibitor, worsened anemia and GI bleeding. The dosage used in this study, 20 mg kg À1 b.w. (total 40 mg kg À1 b.w., daily), is well below the dosage of erlotinib used in previous studies (100 mg kg À1 b.w., daily), in which no significant intestinal toxicity was observed [26] . Therefore, this deleterious influence is not due to over-dosing. Our results may indicate that erlotinib should be used with caution for HHT patients. TKIs in this study were not effective for woundinduced skin AVMs. This suggests under-dosing, potentially from poor drug access in the skin tissue for such drugs. To test whether topical applications of TKIs could be effective for inhibiting wound-induced AVM formation, we utilized a dorsal skinfold window chamber model. In this model, the progress of wound-induced AVM development can be observed daily with a hyperspectral imaging system, which detects the oxygen saturation content in the blood vessels, and the drug can be directly applied to the wounded skin area [7, 27] . All vehicle-injected Alk1-iKO mice developed AVMs as expected (Fig. 4A) . A varied response to GW771806 treatment was observed. Although one of the GW771806-treated mice showed remarkable reduction of AVM formation (Fig. 4B) , another mouse in the treated group had no treatment effect (Fig. 4C) , and the rest had a mid-level influence. Overall, there was a trend of reduction in AVM formation represented by vascular density, but it did not reach significance (Fig. 4D) . Because the window chamber is not sealed from neighboring skin, the drug could be diffused away from the chamber, and thus once-a-day treatment may not be sufficient to sustain the effect on the wound site. This warrants further testing with an increased sample size, and a different dosage, frequency and mode of topical application of these drugs for skin AVMs. 
